Trade Mark Journal No.2026/011 13 March 2026
WO0000001887944 (5,44)
Office of origin: United States of America
Date of International Registration:6 October 2025
Date of designation in the UK:
6 October 2025
The PLUS symbol in the trade mark shall be reproduced neither in white on a red background nor in red on a white background; nor shall it be reproduced in any other colour likely to be confused with the Swiss cross or the emblem of the Red Cross.
International priority date claimed: 11 April 2025
(United States of America)
(99133260)
- Class 5
- Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of graft versus host disorder (GVHD); pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparations for the treatment of hypophosphatemia disorders; pharmaceutical preparations for the treatment of myeloproliferative disorders; pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of fibrotic disorders.
- Class 44
- Providing medical information via a website.
Incyte Holdings Corporation
Representative: Page, White & Farrer Limited, Bedford House, John Street London WC1N 2BF UNITED KINGDOM